In Section C, members will obtain ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Participants will acquire treatment until eventually disease progression or the participants are unable to tolerate the study drugs. There might be bigger treatment burden for members During this trial in comparison https://jimiq888epz1.develop-blog.com/profile